News

From prognosis to prevention: Alzheimer’s biomarkers hold significant promise for the future

1200 675 Peter Stevenson, PhD

Biomarkers could change the landscape of Alzheimer’s disease (AD) forever, but we are only just scratching the surface of their potential, the audience heard during the prestigious Charles-Édouard Brown-Séquard Lecture…

read more

The many faces of progressive supranuclear palsy

1200 800 Mea Holm, PhD

Progressive supranuclear palsy (PSP)—a neurodegenerative disease characterized by tau pathology—can have a variety of clinical presentations, delegates heard at an EAN 2018 forum talk delivered by Prof. Günther Höglinger from…

read more

PML risks linked to MS drug duration

1200 797 Peter Stevenson, PhD

Development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients is linked to treatment medications, not the MS itself, delegates heard at the recent Consortium of Multiple Sclerosis Centers…

read more

New app aims to facilitate cognitive screening of MS patients

3008 2008 Mea Holm, PhD

Dr. Stephen Rao from the Cleveland Clinic (Ohio, USA) presented a new tablet-based screening method for cognitive dysfunction at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Nashville,…

read more

Preclinical Alzheimer’s unlikely to lead to dementia, new study reports

1200 829 Peter Stevenson, PhD

New data from a multi-study analysis has unveiled that preclinical Alzheimer’s disease (AD) will not lead to severe dementia in the majority of cases. The paper marks the first time…

read more

FDA approves blockbuster migraine treatment

1200 800 Mea Holm, PhD

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

read more

Machine learning offers automated diagnosis in stroke and dementia

1200 800 Peter Stevenson, PhD

Researchers have harnessed the power of artificial intelligence (AI) to identify a key cause of dementia and stroke – and with stunning accuracy – a new study reports. Created by…

read more

“Ask the audience”: Stroke debates feature at ESOC 2018

1600 2400 Peter Stevenson, PhD

Controversies in stroke were laid bare at the recent European Stroke Organisation Conference (ESOC) in Gothenburg, Sweden, in a special session that saw experts rallying to convince the audience of…

read more

First MS treatment approved for children & adolescents

1600 1067 Peter Stevenson, PhD

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…

read more

​Saunas linked to reduced stroke risk

1200 800 Peter Stevenson, PhD

Regular use of saunas could be key in reducing stroke risk, a new European study reports. Baseline sauna habits of 1,628 men and women (age 53–74 years; mean 62.7) without prior…

read more
Brainwork is supported by unrestricted grants from: